Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 4 | 14 | 18 | 1995 | 3 | 12 | 15 | 1996 | 4 | 12 | 16 | 1997 | 5 | 6 | 11 | 1998 | 2 | 13 | 15 | 1999 | 7 | 6 | 13 | 2000 | 8 | 10 | 18 | 2001 | 8 | 13 | 21 | 2002 | 6 | 12 | 18 | 2003 | 9 | 15 | 24 | 2004 | 11 | 19 | 30 | 2005 | 16 | 14 | 30 | 2006 | 15 | 13 | 28 | 2007 | 20 | 11 | 31 | 2008 | 13 | 24 | 37 | 2009 | 35 | 18 | 53 | 2010 | 27 | 22 | 49 | 2011 | 14 | 18 | 32 | 2012 | 13 | 13 | 26 | 2013 | 15 | 9 | 24 | 2014 | 32 | 8 | 40 | 2015 | 11 | 8 | 19 | 2016 | 16 | 12 | 28 | 2017 | 20 | 14 | 34 | 2018 | 18 | 8 | 26 | 2019 | 17 | 8 | 25 | 2020 | 21 | 12 | 33 | 2021 | 14 | 9 | 23 | 2022 | 6 | 25 | 31 | 2023 | 5 | 16 | 21 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study Neurology. 2024 01 23; 102(2):e207937.
-
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med. 2024 Jan; 30(1):229-239.
-
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 12; 21(12):1281-1301.
-
Huang Y, Zhang L, Karuna S, Andrew P, Juraska M, Weiner JA, Angier H, Morgan E, Azzam Y, Swann E, Edupuganti S, Mgodi NM, Ackerman ME, Donnell D, Gama L, Anderson PL, Koup RA, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Lemos MP. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01. Nat Commun. 2023 Nov 28; 14(1):7813.
-
Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Srinivasan A, Hadjiiski L, Jordan D, Bradley EA, Stan MN, Eckstein A, Pitz S, Vorl?nder C, Wester ST, Nguyen J, Tucker N, Sales-Sanz M, Feldon SE, Nelson CC, Hardy I, Abia-Serrano M, Tedeschi P, Janes JM, Xu J, Vue P, Macias WL, Douglas RS. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023 Nov 17; 108(12):3122-3134.
-
Perez de Acha O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, Parzych SE, Abbott D, Idler BM, Ribadeneyra D, Niesvizky R, Forsberg PA, Mark TM, Sherbenou DW. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv. 2023 11 14; 7(21):6430-6440.
-
Wemlinger SM, Cambier JC. Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer. Eur J Immunol. 2024 Jan; 54(1):e2249947.
-
Borowska MT, Boughter CT, Bunker JJ, Guthmiller JJ, Wilson PC, Roux B, Bendelac A, Adams EJ. Biochemical and biophysical characterization of natural polyreactivity in antibodies. Cell Rep. 2023 10 31; 42(10):113190.
-
Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023 08 15; 29(16):2988-3003.
-
Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, Pordy R, Fazio S, Geba GP. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Med. 2023 08; 12(16):16859-16868.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|